---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-186939"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T03:38:53.088583+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q1 revenue falls to $124.2M, net loss narrows; pipeline advances

## Summary
- Consolidated revenue $124.2M vs $149.9M YoY; net loss $54.8M ($0.07/sh) from $67.6M ($0.10/sh).
- Pharma revenue $38.0M (+9% YoY); Diagnostics $72.2M, down from $102.8M due to Labcorp oncology asset sale.
- Operating loss improved to $51.0M from $67.2M; cash $341.9M; $92M of stock repurchased under $200M authorization.
- Phase 1 trials started for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma); in vivo CAR-T platform advancing.
- FY2026 guidance reaffirmed: total revenue $530-560M; total costs $725-750M.

## SEC filing metadata
- accession: 0001193125-26-186939
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/0001193125-26-186939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/opk-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-186939
- JSON: https://secwatch.observer/filing/0001193125-26-186939.json
- Plain text: https://secwatch.observer/filing/0001193125-26-186939.txt

## Key facts
- Earnings Releases
  OPKO HEALTH, INC. reported the three months ended March 31, 2026 results: revenue $124.2 million, net income $54.8 million, EPS $0.07 per share.
  - Period: the three months ended March 31, 2026
  - Revenue: $124.2 million
  - Net income: $54.8 million
  - EPS: $0.07 per share
  - Result: reported results
  source text: each is responsible for 50% of the program's development costs. First Quarter Financial Results • Consolidated: Consolidated total revenues for the first quarter of 2026 were $124.2 million compared with $149.9 million for the 2025 period, with the decrease principally resulting from the sale of certain BioReference assets in 2025. Operating loss for the first
  evidence_url: https://www.sec.gov/Archives/edgar/data/944809/000119312526186939/0001193125-26-186939-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.